Maria Moricz, MD, PharmD

VP, Evidence Generation RWE Oncology Team Lead, Pfizer



Dr. Moricz transitioned from Global Product Development to Pfizer’s RWE Center of Excellence in early 2022 to lead its elevation into a more robust enterprise-level Evidence Generation Platform within the Chief Business Office Biopharmaceuticals Division. 

As the organization's lead for RWE Oncology, Dr. Moricz is driving broadened capability to integrate RWE, bioanalytics, and innovative approaches like AI into development and access strategies that bring new medicines to patients faster. 

With over 25 years’ of industry clinical research and development experience across all oncology study phases at Novartis, Daichii Sankyo, Bristol-Myers Squibb, and Pfizer, Dr. Moricz has spearheaded multiple global programs that achieved approvals and expanded indications in malignant hematology and solid tumors. 

Her strategic focus spans molecularly-targeted therapy, immuno-oncology, and translational/precision medicine, with direct experience incorporating RWE into industry clinical development for pivotal milestones and health authority decisions. Her insights can expire the leveraging of RWE to drive advancements in RWE and cancer bioinformatics in industry.